Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes
作者:Sameer Agarwal、Santosh Sasane、Jeevan Kumar、Prashant Deshmukh、Hitesh Bhayani、Poonam Giri、Suresh Giri、Shubhangi Soman、Neelima Kulkarni、Mukul Jain
DOI:10.1016/j.bmcl.2018.04.011
日期:2018.6
TGR5 is a member of G protein-coupled receptor (GPCR) superfamily, a promising molecular target for metabolic diseases. Activation of TGR5 promotes secretion of glucagon-like peptide-1 (GLP-1), which activates insulin secretion. A series of 2-thio-imidazole derivatives have been identified as novel, potent and orally efficacious TGR5 agonists. Compound 4d, a novel TGR5 agonist, in combination with Sitagliptin, a DPP-4 inhibitor, has demonstrated an adequate GLP-1 secretion and glucose lowering effect in animal models, suggesting a potential clinical option in treatment of type-2 diabetes. (C)2018C)2018 Elsevier Ltd. All rights reserved.